

Seven days after the last immunization, heads of the mice were severed from the body and then placed in fixative solution (4% paraformaldehyde). Histopathological examination was performed by the Applied Medical Research Laboratory (Osaka, Japan). For single immunization protocol, BALB/c mice were immunized with OVA with or without mTNF-K90R at a dose of 5 μg . At 2 h after single immunization, histopathological examination was performed using the same protocol.

2.11. Statistical analysis

All results are expressed as mean \pm SEM. Statistical significance in differences were evaluated by Newman–Keuls Multiple Comparison Test after analysis of variance (ANOVA).

3. Results

3.1. Mucosal adjuvant activity of mTNF-K90R

To examine the properties of mTNF-K90R as a mucosal vaccine adjuvant, mice were intranasally immunized with 100 μg OVA plus wTNF- α (1 μg mice⁻¹), mTNF-K90R (1 μg mice⁻¹, 5 μg mice⁻¹), or CTB (1 μg mice⁻¹) three times at weekly intervals. Seven days after the last immunization, we examined the level of anti-OVA Abs response in the serum by ELISA (Fig. 1A). Intranasal immunization with OVA plus 1 μg mTNF-K90R induced higher levels of anti-OVA IgG Ab response in serum than after immunization with OVA alone or OVA plus 1 μg wTNF- α . Furthermore, OVA-specific IgG Ab levels of mTNF-K90R immunized mice were of a similar magnitude to those immunized with CTB, a common laboratory mucosal adjuvant.

Serum IgG subclass responses have been used to assess the type of immune response elicited by immunization. For example, IgG1 is indicative of a Th2-type response whereas IgG2a is indicative of a Th1-type response. To assess the type of immune response induced

by mTNF-K90R, serum OVA-specific IgG subclass responses were also examined (Fig. 1B). OVA-specific IgG1 Ab levels of 1 μg mTNF-K90R immunized mice were higher than those immunized with OVA alone or OVA plus 1 μg wTNF- α , and as well as in mice immunized with CTB. However, the level of OVA-specific IgG2a was low in all groups, indicating that mTNF-K90R may induce immune responses with an antigen-specific Th2 component.

Next, we examined the OVA-specific IgA secretion in nasal washes, vaginal washes, and fecal extracts from immunized mice (Fig. 2). As expected, immunization with OVA plus CTB induced strong anti-OVA IgA secretion in all mucosal tissues. Nasal immunization with OVA plus 1 μg of mTNF-K90R tended to induce high levels of OVA-specific IgA secretion in nasal tissue and fecal extract compared with after immunization with OVA plus 1 μg wTNF- α . The IgA level of 1 μg mTNF-K90R immunized mice in nasal tissue was of a similar magnitude to those immunized with CTB. In contrast, the IgA level in vaginal tissue and fecal extract was lower for the 1 μg mTNF-K90R treated mice compared with that of CTB treated mice. Nasal immunization with OVA plus 5 μg of mTNF-K90R induced high OVA-specific IgA secretion in multiple mucosal tissues compared to 1 μg of mTNF-K90R and comparable anti-OVA Abs responses to those induced with OVA plus CTB. These results indicate that mTNF-K90R is an attractive mucosal vaccine adjuvant for the induction of antigen-specific systemic IgG and mucosal IgA responses.

3.2. Antigen-specific cytokine responses of mTNF-K90R

To clarify the mechanism of immune response elicited by mTNF-K90R, the release profiles of cytokines from splenocytes of OVA-immunized mice were analyzed. Culture supernatants from




Fig. 1. Serum OVA-specific IgG Abs response after nasal immunization with OVA plus adjuvant. BALB/c mice were intranasally immunized with OVA alone, OVA plus 1 μg CTB, OVA plus 1 μg wTNF- α , OVA plus 1 μg mTNF-K90R or OVA plus 5 μg mTNF-K90R once a week for three consecutive weeks. Serum was collected 1 wk after the last immunization and analyzed by ELISA for OVA-specific IgG (A) and IgG subclass (B) at a 1:100 dilution of serum. Data represents the mean of absorbance 450 nm (reference wave, 655 nm). N.D.; not detected. Data are presented as means \pm SEM ($n = 7$; ** $P < 0.01$ versus value for OVA alone treated group by ANOVA; # $P < 0.05$ versus value for OVA plus wTNF- α treated group by ANOVA).




Fig. 2. OVA-specific mucosal IgA Abs response after nasal immunization with OVA plus adjuvant. BALB/c mice were intranasally immunized with OVA alone, OVA plus 1 µg CTB, OVA plus 1 µg wTNF- α , OVA plus 1 µg mTNF-K90R or OVA plus 5 µg mTNF-K90R once a week for three consecutive weeks. Mucosal secretions were collected 1 wk after the last immunization and OVA-specific IgA Abs responses in nasal wash, vaginal wash and fecal extract were determined by ELISA at a 1:8 dilution. Data represents the mean of absorbance 450 nm (reference wavelength, 655 nm). Data are presented as means \pm SEM ($n = 7$; * $P < 0.05$, ** $P < 0.01$ versus value for OVA alone treated group by ANOVA; # $P < 0.05$, ## $P < 0.01$ versus value for OVA plus wTNF- α treated group by ANOVA).

OVA-stimulated splenocytes collected from immunized mice were assessed for Th2-type cytokines IL-4, IL-5, IL-10, granulocyte macrophage colony-stimulating factor (GM-CSF) (Fig. 3A) and Th1-type cytokines IL-12 and IFN- γ (Fig. 3B), using a multiplexed immunobeads assay. Splenocytes from mice immunized with OVA plus 1 µg mTNF-K90R exhibited higher levels of Th2-type cytokines (IL-4, IL-5, IL-10 and GM-CSF) than those responses induced with OVA plus 1 µg wTNF- α or CTB (Fig. 3A). In contrast, there was hardly any difference in Th1-type cytokine (IL-12 and IFN- γ) secretion amongst all of the immunized mice (Fig. 3B). To further characterize the type of immune response, the level of OVA-specific IFN- γ and IL-4-secreting splenocytes from OVA-immunized mice with the various adjuvants was determined using a cytokine-specific ELISPOT assay (Fig. 4). The level of OVA-specific IL-4-secreting splenocytes from OVA-immunized mice with mTNF-K90R was greater than those responses observed after administration of wTNF- α or CTB. By contrast, the level of IFN- γ -secreting splenocytes in OVA-immunized mice with mTNF-K90R was no different from the levels observed for mice immunized with OVA alone. These results suggested that mTNF-K90R induced a more strongly polarized Th2-type immune response when mTNF-K90R was used as a mucosal vaccine adjuvant.

3.3. Mucosal adjuvant efficacy against influenza virus

We anticipated that a mucosal influenza virus-neutralizing antibody response would generate an ideal vaccine against these infectious diseases. To estimate the mucosal adjuvant efficacy of mTNF-K90R for influenza virus HA vaccine, the antibody response against HA was examined in mice intranasally immunized with mTNF-K90R (Fig. 5). Mice receiving HA plus 5 µg of mTNF-K90R

induced a significantly greater anti-HA IgG or IgA response in serum, saliva or nasal wash compared with mice receiving HA alone or HA plus CTB. These results indicated that application of mTNF-K90R as a nasal vaccine adjuvant to viral infectious diseases might be an effective strategy.

3.4. Localization of antigens into nasopharyngeal-associated lymphoreticular tissue (NALT)

Because NALT plays an important role in the initial induction of the mucosal immune response, it was important to determine the tissue localization of the antigens. To characterize the mechanism of mTNF-K90R in the induction of OVA-specific mucosal and systemic immune responses, we examined the localization of OVA in NALT derived from mice that were immunized with OVA in the absence or presence of mTNF-K90R (Fig. 6). Fluorescence microscopic analysis revealed that FITC-OVA was mainly located beneath the nasal epithelium surrounding NALT in mice treated with FITC-OVA alone. By contrast, in addition to the subepithelial region, FITC-OVA was also observed within NALT after co-administration of mTNF-K90R. These results indicate that mTNF-K90R might induce the effective entry of antigens into NALT due to increasing nasal epithelial permeability. We believe that the observed response of mTNF-K90R in the nasal epithelial reflects one of the mechanisms for the induction of antigen-specific mucosal and systemic immune response in mice.

3.5. Safety examination of mTNF-K90R

While enterotoxin-based adjuvants display a strong mucosal response, they also induce severe central nervous system damage




Fig. 3. Cytokine response induced after nasal immunization with OVA plus adjuvant. BALB/c mice were intranasally immunized with OVA alone, OVA plus 1 μg CTB, OVA plus 1 μg wTNF-α or OVA plus 1 μg mTNF-K90R once a week for three consecutive weeks. One week after the last immunization, splenocytes from each group were cultured with 1 mg ml⁻¹ OVA. Culture supernatants were harvested following 3 days of incubation, and OVA-specific Th2-type (A) and Th1-type (B) cytokine productions in culture supernatant were analyzed by using the Bio-Plex Multiplex Cytokine Assay. Data are presented as means ± SEM (n = 6; *P < 0.05, **P < 0.01 versus value for OVA alone treated group by ANOVA).




Fig. 4. Analysis of OVA-specific cytokine-secreting cells in mice nasally immunized with OVA plus adjuvant. BALB/c mice were intranasally immunized with OVA alone, OVA plus 1 μg CTB, OVA plus 1 μg wTNF-α or OVA plus 1 μg mTNF-K90R once a week for three consecutive weeks. One week after the last immunization, splenocytes from each group were cultured with 1 mg ml⁻¹ OVA. The levels of OVA-specific IL-4 (a) and IFN-γ-producing cells (b) were examined by individual cytokine-specific ELISPOT assay. Data are presented as means ± SEM (n = 3; **P < 0.01 versus value for OVA plus CTB treated group by ANOVA; #P < 0.05 versus value for OVA plus wTNF-α treated group by ANOVA).




Fig. 5. mTNF-K90R induced mucosal IgA and IgG responses against influenza virus HA in mice. BALB/c mice were immunized intranasally with HA together with 1 µg CTB or 5 µg mTNF-K90R. One week after the last immunization, HA-specific IgG in serum at a 1:500 dilution and IgA in nasal or saliva at a 1:8 dilution were assessed by ELISA at a 1:8 dilution. Data represents the mean of absorbance 450 nm (reference wavelength, 655 nm). N.D.; not detected. Data are presented as means \pm SEM ($n = 4-6$; * $P < 0.05$, ** $P < 0.01$ versus value for HA alone treated group by ANOVA).

due to the presence of a specific receptor, GM1 ganglioside, which is highly expressed in neuronal tissue [20]. This neurotoxicity has severely restricted the use enterotoxins as adjuvants for mucosal vaccines in clinical practice. To evaluate the *in vivo* toxicity of mTNF-K90R, inflammatory response and tissue injury were assessed in the nasal tissue (Fig. 7). Tissue sections of the nasal cavity were prepared at various time points after immunization of OVA plus mTNF-K90R. However, no tissue injury could be detected in any of the sections. These observations indicate no membrane barrier disruption and/or inflammatory changes, not even after 2 h single immunization with 5 µg mTNF-K90R (Fig. 7A and B). Furthermore, increasing the dose of mTNF-K90R given intranasally from 1 µg to 25 µg did not seem to have an adverse effect on the mice after three immunizations (Fig. 7C and D). Thus, although further evaluation is required, the results of this initial study demonstrated that the toxicity of mTNF-K90R is likely to be relatively low.

4. Discussion

In this study, we examined the mucosal adjuvant activity of mTNF-K90R and showed that intranasal co-administration of mTNF-K90R with antigen strongly induced both antigen-specific IgG in serum and IgA at mucosal site (nasal cavity, oral cavity, vagina and intestine). The enhanced adjuvant effect of mTNF-K90R might be caused by improved bioactivity and protease resistance compared to wTNF- α . Although mTNF-K90R showed a potent adjuvant effect on mucosal immunity, it does not elicit excessive inflammatory symptoms, such as formation of edema or fibrosis. Therefore, we believe that mTNF-K90R is a potent mucosal adjuvant for vaccines against various infectious diseases.

The development of a safe and effective vaccine is critical in preventing the spread of influenza virus. It is generally thought that or anti-influenza virus-neutralizing antibody must be induced at mucosal surfaces in order to prevent influenza virus infection. Previous studies also reported that antigen-specific systemic IgG and mucosal IgA Abs have potentially important roles for protection against the influenza virus [21,22]. Therefore, our results suggest that mTNF-K90R might be a superior mucosal vaccine adjuvant against infectious diseases caused by influenza virus.

TNF- α is anticipated to be used as a therapeutic drug to treat cancer. TNF- α has been used clinically for the treatment of non-resectable high-grade sarcoma and melanoma by locoregional applications in combination with melphalan under the approval of the European Agency for the Evaluation of Medicinal Products because systemic administration of TNF- α at therapeutically effective doses is limited by its unacceptable toxic side effects [23,24]. Further, in a recent report, it has been suggested that TNF- α had the potentials of the genetic toxicity, because TNF- α caused DNA damage through its ability to induce reactive oxygen species [25]. Thus, it is important to examine the safety of mTNF-K90R in a protocol using a mucosal vaccine adjuvant. Previously, we reported that mTNF-K90R had 1.3-fold lower *in vivo* toxicity after systemic administration compared with that of wTNF- α because of a change in the pharmacokinetics. Similarly, no adverse effect on the nasal mucosa was observed in this study after intranasal administration of mTNF-K90R. Although detailed examinations are required, mTNF-K90R is expected to be a useful mucosal vaccine adjuvant. Furthermore, we have shown that conjugating cytokines with polyethylene glycol (PEG) improves their safety *in vivo* [17,18,26–28]. We have also developed a novel site-specific PEGylation process to overcome the




Fig. 6. Localization analysis of OVA in NALT. BALB/c mice were administered 50 µg FITC-OVA and a combination of 5 µg mTNF-K90R as a nasal vaccine adjuvant. Frozen sections of NALT resected from mice treated with FITC-OVA alone (A) and a combination of mTNF-K90R (B). The FITC-OVA (green) signals were detected by fluorescence microscopy. The nucleus was counterstained using PI (red). The original magnification of these photographs was 20 \times .




Fig. 7. Histopathological analysis of nasal cavity treated with mTNF-K90R. Frontal cross-sections of the nasal cavity from mice, taken 2 h after administration (A, B) or one week after three times administration of PBS, OVA alone, and OVA together with 1 µg, 5 µg or 25 µg mTNF-K90R (C, D). An overall view of the nasal passage is shown in (A) and (C). The region of nasal olfactory epithelia is shown in (B) and (D). Sections were prepared and the tissues were stained with H&E to assess the degree of tissue injury and local inflammation.

problems of PEGylation [17,18,26,28]. Previously we showed that the application of this technology to mTNF-K90R improved the safety and the anti-tumor effects of mTNF-K90R [18]. We are currently examining the safety and efficacy of site-specific PEGylated mTNF-K90R as a mucosal vaccine adjuvant.

The effects of mTNF-K90R at mucosal tissue was also analyzed. We reasoned that the adjuvant effect of mTNF-K90R may be related to its stimulation of antigen-presenting cells, such as DC. Indeed, DC plays a crucial role in eliciting T cell-dependent immunity. TNF- α is known to have profound effects on DC function and contributing to their activation, maturation and migration to, and accumulation within, draining lymph nodes [29,30]. Moreover, DC stimulated by TNF- α prior to anti-tumor vaccination or transfection with the TNF- α gene are reported to induce anti-tumor immunity [14,15]. However, we found that mTNF-K90R significantly enhanced the permeability of the nasal epithelial layer and diffusion of antigen into NALT. Consistent with our results, some reports have shown that TNF- α causes an increase in intestinal permeability [25,31]. Taken together, these results suggest that the strong mucosal adjuvant activity of mTNF-K90R is caused, at least in part, by increased epithelial permeability. In addition, TNF- α causes up-regulation of human polymeric Ig receptor on mucosal epithelial cells [32]. Polymeric Ig receptor transports polymeric IgA into external secretions as secretory IgA, which is critical for the defense

of mucosal tissues [33]. We believe that multiple actions of mTNF-K90R contribute to its potent adjuvant activity. Currently, we are attempting to elucidate these various mechanisms.

Induction of both Th1- and Th2-type responses is the major goal for the development of mucosal vaccines because these responses would provide protective immunity against viral and bacterial infections by maximizing antigen-specific Ab and cytolytic T lymphocytes (CTL) responses. Although mTNF-K90R is not likely to induce CTLs, it could efficiently induce Abs responses. To induce both antigen-specific Ab and CTL responses, combinatorial administration of mTNF-K90R with another mucosal adjuvant, which can induce Th1-type immune responses, is applicable. We have already screened the TNF superfamily and other cytokines and succeeded in finding candidates that can effectively induce CTL at the mucosal site. The combinatorial effect of the cytokines and mTNF-K90R as a mucosal vaccine adjuvant is now under examination.

Recently, vaccine therapy has been attempted not only to combat cancer or viral infections but also for other diseases such as Alzheimer-type dementia. Schenk et al. demonstrated that intraperitoneal vaccination of β -amyloid peptide plus Freund's adjuvant to a murine Alzheimer's disease model resulted in a dramatic reduction of cerebral amyloidosis [34]. This therapeutic approach is clearly efficacious; however, the safety of this strategy is of paramount importance. In a clinical trial, approximately 6% of patients

administered a synthetic β -amyloid peptide plus adjuvant developed aseptic meningoencephalitis, most likely mediated by brain-infiltrating activated T cells [35,36]. This adverse effect seemed to be associated with the activation of Th1-type immunity by vaccination with β -amyloid peptide [37,38]. Nikolic et al. demonstrated that immunization capable of inducing Th2-type immunity predominantly constitutes an effective and potentially safe treatment strategy for Alzheimer's disease [39]. Therefore, our mTNF-K90R is a promising development in the establishment of an easy-to-use, efficacious, safe immunotherapy for Alzheimer's disease. However, further analyses are necessary in order to elucidate the Th2-dominant mechanism of mTNF-K90R.

5. Conclusions

In summary, our study showed that mTNF-K90R, engineered by using a phage display technique, induced two layers of protective immunity when administered intranasally with a vaccine antigen. Our results indicate that mTNF-K90R is a safe and effective mucosal adjuvant. Additionally, our technique of creating bioactive mutant cytokines might be an attractive generic approach for designing novel mucosal adjuvants.

Acknowledgements

This study was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) and Japan Society for the Promotion of Science (JSPS), some Health Labour Sciences Research Grants from the Ministry of Health, Labor, and Welfare in Japan by the Research on Health Sciences focusing on Drug Innovation from the Japan Health Sciences Foundation and by the Takeda Science Foundation.

Appendix

Figures with essential color discrimination. Figs. 6 and 7 in this article may be difficult to interpret in black and white. The full color images can be found in the on-line version, at doi:10.1016/j.biomaterials.2009.07.009.

References

- [1] Eriksson K, Holmgren J. Recent advances in mucosal vaccines and adjuvants. *Curr Opin Immunol* 2002;14:666–72.
- [2] Haynes BF, Shattock RJ. Critical issues in mucosal immunity for HIV-1 vaccine development. *J Allergy Clin Immunol* 2008;122:3–9.
- [3] Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. *Vaccine* 2007;25:5467–84.
- [4] Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. *Nat Med* 2005;11:S45–53.
- [5] Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. *Nat Rev Immunol* 2006;6:148–58.
- [6] Ada G. Vaccines and vaccination. *N Engl J Med* 2001;345:1042–53.
- [7] Gorbach SL, Khurana CM. Toxigenic *Escherichia coli* in infantile diarrhea in Chicago. *J Lab Clin Med* 1971;78:981–2.
- [8] Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. *N Engl J Med* 2004;350:896–903.
- [9] Boyaka PN, Marinaro M, Jackson RJ, Menon S, Kiyono H, Jirillo E, et al. IL-12 is an effective adjuvant for induction of mucosal immunity. *J Immunol* 1999;162:122–8.
- [10] Staats HF, Bradney CP, Gwinn WM, Jackson SS, Sempowski GD, Liao HX, et al. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. *J Immunol* 2001;167:5386–94.
- [11] Toka FN, Pack CD, Rouse BT. Molecular adjuvants for mucosal immunity. *Immunol Rev* 2004;199:100–12.
- [12] Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. *Cell Death Differ* 2003;10:45–65.
- [13] Calzascia T, Pellegrini M, Hall H, Sabbagh L, Ono N, Elford AR, et al. TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. *J Clin Invest* 2007;117:3833–45.
- [14] Brunner C, Seiderer J, Schlamp A, Bidlingmaier M, Eigler A, Haimerl W, et al. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation *in vitro* and therapeutic anti-tumor immune responses *in vivo*. *J Immunol* 2000;165:6278–86.
- [15] Chen Z, Huang H, Chang T, Carlsen S, Saxena A, Marr R, et al. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor. *Cancer Gene Ther* 2002;9:778–86.
- [16] Nimal S, Heath AW, Thomas MS. Enhancement of immune responses to an HIV gp120 DNA vaccine by fusion to TNF alpha cDNA. *Vaccine* 2006;24:3298–308.
- [17] Yamamoto Y, Tsutsumi Y, Yoshioka Y, Nishibata T, Kobayashi K, Okamoto T, et al. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. *Nat Biotechnol* 2003;21:546–52.
- [18] Shibata H, Yoshioka Y, Ikemizu S, Kobayashi K, Yamamoto Y, Mukai Y, et al. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. *Clin Cancer Res* 2004;10:8293–300.
- [19] Shibata H, Yoshioka Y, Ohkawa A, Minowa K, Mukai Y, Abe Y, et al. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. *J Biol Chem* 2008;283:998–1007.
- [20] van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. *J Immunol* 2000;165:4778–82.
- [21] Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. *Nat Med* 2003;9:343–6.
- [22] Hasegawa H, Ichinohe T, Tamura S, Kurata T. Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic. *Expert Rev Vaccines* 2007;6:193–201.
- [23] Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. *Curr Opin Immunol* 1998;10:573–80.
- [24] Eggermont AM. TNF registered in Europe: does TNF get a second chance? *J Immunother* 2000;23:505–6.
- [25] Yan B, Wang H, Rabbani ZN, Zhao Y, Li W, Yuan Y. Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. *Cancer Res* 2006;66:11565–70.
- [26] Yoshioka Y, Tsutsumi Y, Ikemizu S, Yamamoto Y, Shibata H, Nishibata T, et al. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency. *Biochem Biophys Res Commun* 2004;315:808–14.
- [27] Yoshioka Y, Tsutsumi Y, Nakagawa S, Mayumi T. Recent progress on tumor missile therapy and tumor vascular targeting therapy as a new approach. *Curr Vasc Pharmacol* 2004;2:259–70.
- [28] Mukai Y, Yoshioka Y, Tsutsumi Y. Phage display and PEGylation of therapeutic proteins. *Comb Chem High Throughput Screen* 2005;8:145–52.
- [29] Trevejo JM, Marino MW, Philpott N, Josien R, Richards EC, Elkon KB, et al. TNF-alpha-dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection. *Proc Natl Acad Sci U S A* 2001;98:12162–7.
- [30] Lee LF, Xu B, Michie SA, Beilhack GF, Warganich T, Turley S, et al. The role of TNF-alpha in the pathogenesis of type 1 diabetes in the nonobese diabetic mouse: analysis of dendritic cell maturation. *Proc Natl Acad Sci U S A* 2005;102:15995–6000.
- [31] Gitter AH, Bendfeldt K, Schmitz H, Schulzke JD, Bentzel CJ, Fromm M. Epithelial barrier defects in HT-29/B6 colonic cell monolayers induced by tumor necrosis factor-alpha. *Ann N Y Acad Sci* 2000;915:193–203.
- [32] Takenouchi-Ohkubo N, Moro I, Mukae S, Kaneko Y, Komiya K. Tumour necrosis factor-alpha-mediated human polymeric immunoglobulin receptor expression is regulated by both mitogen-activated protein kinase and phosphatidylinositol-3-kinase in HT-29 cell line. *Immunology* 2008;123:500–7.
- [33] Mestecky J, McGhee JR. Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. *Adv Immunol* 1987;40:153–245.
- [34] Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. *Nature* 1999;400:173–7.
- [35] Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. *Neuron* 2003;38:547–54.
- [36] Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins I, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. *Neurology* 2005;64:94–101.
- [37] Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. *Nat Med* 2003;9:448–52.
- [38] Monsonego A, Imitola J, Petrovic S, Zota V, Nemirovsky A, Baron R, et al. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci U S A* 2006;103:5048–53.
- [39] Nikolic WV, Bai Y, Obregon D, Hou H, Mori T, Zeng J, et al. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. *Proc Natl Acad Sci U S A* 2007;104:2507–12.



ELSEVIER

Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc

TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant

Hiroyuki Kayamuro^{a,b,1}, Yasuo Yoshioka^{a,c,1}, Yasuhiro Abe^{a,1}, Kazufumi Katayama^d, Tokuyuki Yoshida^{a,b}, Kohei Yamashita^{a,b}, Tomoaki Yoshikawa^{a,b}, Takachika Hiroi^d, Norio Itoh^c, Yuichi Kawai^e, Tadanori Mayumi^e, Haruhiko Kamada^{a,c}, Shin-ichi Tsunoda^{a,c,*}, Yasuo Tsutsumi^{a,b,c}

^a Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation (NiBio), 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan

^b Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan

^c The Center for Advanced Medical Engineering and Informatics, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan

^d Department of Allergy and Immunology, The Tokyo Metropolitan Institute of Medical Science, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8613, Japan

^e Faculty of Pharmaceutical Sciences, Kobe-Gakuin University, 518, Arise, Ikawadani, Nishiku, Kobe 651-2180, Japan

ARTICLE INFO

Article history:

Received 17 April 2009

Available online 4 May 2009

Keywords:

Cytokine

IgA

Mucosal immunity

Vaccine

ABSTRACT

The identification of cytokine adjuvants capable of inducing an efficient mucosal immune response against viral pathogens has been long anticipated. Here, we attempted to identify the potential of tumor necrosis factor superfamily (TNFS) cytokines to function as mucosal vaccine adjuvants. Sixteen different TNFS cytokines were used to screen mucosal vaccine adjuvants, after which their immune responses were compared. Among the TNFS cytokines, intranasal immunization with OVA plus APRIL, TL1A, and TNF- α exhibited stronger immune response than those immunized with OVA alone. TL1A induced the strongest immune response and augmented OVA-specific IgG and IgA responses in serum and mucosal compartments, respectively. The OVA-specific immune response of TL1A was characterized by high levels of serum IgG1 and increased production of IL-4 and IL-5 from splenocytes of immunized mice, suggesting that TL1A might induce Th2-type responses. These findings indicate that TL1A has the most potential as a mucosal adjuvant among the TNFS cytokines.

© 2009 Published by Elsevier Inc.

Introduction

The majority of infectious pathogens, including HIV or influenza virus, enter through a mucosal surface. One important aspect of the immune response at mucosal surfaces is the production of secretory immunoglobulin (Ig) A antibodies, as well as the induction of cytotoxic T cells (CTLs) against epithelium-transmitted pathogens; therefore, the development of vaccines that induce effective immune responses at mucosal surfaces is important.

Mucosal vaccines administered either orally or nasally are highly warranted in order to combat these infectious diseases, as they would reduce the transmission of infectious pathogens more efficiently than parenteral administration by stimulating both mucosal and systemic immune responses [1,2]. The mucosal antigen-specific immune response, however, is weak because most protein antigens, such as non-living macromolecules or protein-subunit antigens, evoke only a weak or undetectable adaptive immune response when they are applied mucosally. Therefore, in order to develop mucosal vaccines, it is necessary to develop a

mucosal vaccine adjuvant [3]. Both the cholera toxin and *Escherichia coli* heat-labile toxin are potent mucosal vaccine adjuvants, which have been used in experimental systems. Unfortunately, the watery diarrhea induced by these toxins makes their use as oral adjuvants clinically problematic to humans [4]. In addition, recent reports showed that a human vaccine containing inactivated influenza virus and the heat-labile toxin as an adjuvant resulted in a very high incidence of Bell's palsy [5]. Therefore, mucosal vaccine adjuvants with high efficacy and safety for the purpose of a clinical application are necessary.

Cytokines can trigger the innate and adaptive immune responses and also synergize with costimulatory molecules to improve the immune response. Therefore, cytokines are promising vaccine adjuvants that enhance the immune response against pathogens. The members of the tumor necrosis factor (TNF)/TNF receptor (TNFR) superfamily are critically involved in maintaining the homeostasis of the immune system [6–8]. Currently, more than 40 members of the TNF/TNFR superfamily have been identified and the majority is expressed by immune cells. The biological functions of this system encompass beneficial and protective effects in inflammation and host defense as well as a crucial role in immune organogenesis [7]. Among TNF superfamily cytokines, there are some candidates used as vaccine adjuvants to enhance the primary and memory immune responses against cancer and infectious

* Corresponding author. Address: National Institute of Biomedical Innovation (NiBio), 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan. Fax: +81 72 641 9817.

E-mail address: tsunoda@nibio.go.jp (S.-i. Tsunoda).

¹ These authors contributed equally to this work.

disease. For example, 4-1BBL, CD27L, CD30L, GITRL, LIGHT, OX40L, and TNF- α , which have costimulatory functions for survival, expansion, and effector function of T cells, enhance systemic immunity to co-administered antigens [8]. There is, however, no comparative study to investigate the potential of TNF superfamily cytokines as mucosal vaccine adjuvants.

In this study, to develop effective and safe cytokine-based mucosal vaccine adjuvants, we compared the potential of TNF superfamily cytokines. We showed that intranasal coadministration of APRIL, TL1A, or TNF- α along with antigen induced strong antigen-specific systemic IgG and mucosal IgA antibody responses. In particular, TL1A induced the strongest immune responses at mucosal sites among TNF superfamily cytokines. These data suggest that TL1A is an attractive prototype for a mucosal vaccine adjuvant. This study is the first report to clearly demonstrate the potential of TNF superfamily cytokines as mucosal adjuvants. To develop a mucosal vaccine adjuvant, a pool of such information would be of great benefit.

Materials and methods

Adjuvants. Cholera toxin B subunit (CTB) was purchased from List Biological Laboratories (Campbell, CA). Sixteen types of recombinant TNF superfamily cytokines included human APRIL (18.6 kDa), mouse BAFF (23.2 kDa), mouse 4-1BBL (25.7 kDa), mouse CD27L (19.2 kDa), mouse CD30L (22 kDa), mouse CD40L (25 kDa), mouse EDA (23 kDa), mouse GITRL (16 kDa), mouse LIGHT (21 kDa), mouse LT- α (18.5 kDa), mouse OX40L (18 kDa), mouse TL1A (20 kDa), mouse TNF- α (17.5 kDa), mouse TRAIL (20 kDa), mouse TRANCE (36 kDa), mouse TWEAK (17 kDa) were purchased from R&D Systems (Minneapolis, MN).

Mice and immunization protocols. Female BALB/c mice were purchased from SLC (Hamamatsu, Japan) and used at 6 weeks of age. All of the animal experimental procedures in this study were performed in accordance with the National Institute of Biomedical Innovation guidelines for the welfare of animals. Mice were intranasally immunized with 100 μ g of ovalbumin (OVA; Sigma Chemical Co., St. Louis, MO) and 1 μ g CTB or each TNF superfamily cytokine included human APRIL (5.4×10^{-11} M/mouse), mouse BAFF (4.3×10^{-11} M/mouse), mouse 4-1BBL (3.9×10^{-11} M/mouse), mouse CD27L (5.2×10^{-11} M/mouse), mouse CD30L (4.5×10^{-11} M/mouse), mouse CD40L (4.0×10^{-11} M/mouse), mouse EDA (4.3×10^{-11} M/mouse), mouse GITRL (6.3×10^{-11} M/mouse), mouse LIGHT (4.8×10^{-11} M/mouse), mouse LT- α (5.4×10^{-11} M/mouse), mouse OX40L (5.6×10^{-11} M/mouse), mouse TL1A (5.0×10^{-11} M/mouse), mouse TNF- α (5.7×10^{-11} M/mouse), mouse TRAIL (5.0×10^{-11} M/mouse), mouse TRANCE (2.8×10^{-11} M/mouse), mouse TWEAK (5.9×10^{-11} M/mouse) in a total volume of 20 μ l per mouse (10 μ l/nostril). Mice were intranasally treated with OVA plus each of the TNF superfamily cytokines three times at weekly intervals.

Sample collection. Seven days after the final immunization, plasma and mucosal secretions (nasal washes, vaginal washes, and fecal extracts) were collected to assess antigen-specific IgG and IgA responses. Nasal and vaginal washes were collected by gently flushing the nasal passage or vaginal canal with 200 or 100 μ l of sterile PBS, respectively. Fecal pellets (100 mg) were suspended in 1 ml of PBS and then vortexed for 30 min. The samples were centrifuged at 15,000g for 20 min, and then the supernatants were collected as fecal extracts.

Detection of antigen-specific antibody responses by ELISA. Antigen-specific IgG and IgA levels in plasma, nasal washes, vaginal washes, and fecal extracts were determined by ELISA. ELISA plates (Maxisorp, type 96F; Nalge Nunc International, Tokyo, Japan) were coated with 10 μ g/ml OVA in 0.1 M carbonate buffer, respectively,

and incubated overnight at 4 $^{\circ}$ C. The plates were incubated with blocking solution (Block Ace; Dainippon Sumitomo Pharmaceuticals, Osaka, Japan) at 37 $^{\circ}$ C for 2 h, and serum (1/500) or mucosal secretion dilutions (1/50) were added to the OVA-coated plates. After incubation at 37 $^{\circ}$ C for 2 h, the coated plates were washed with PBS-Tween 20 and incubated with the horse horseradish peroxidase-conjugated goat anti-mouse IgG solution or a biotin-conjugated goat anti-mouse IgA detection antibody (Southern Biotechnology Associates, Birmingham, AL) solution at 37 $^{\circ}$ C for 2 h, respectively. For detection of IgA, the plates were washed with PBS-Tween 20 and then incubated with the horseradish peroxidase-coupled streptavidin (Zymed Laboratories South San Francisco) for 1 h at rt. After incubation, the color reaction was developed with tetramethylbenzidine (MOSS, Inc., Pasadena, MD), stopped with 2 N H₂SO₄, and measured by OD_{450–655} on a micro plate reader.

Isolation of splenocytes. Spleens were aseptically removed and placed in RPMI 1640 (Wako Pure Chemical Industries, Osaka, Japan) supplemented with 10% FBS, 50 μ M 2-mercaptoethanol, and 1% antibiotic cocktail (Nacalai Tesque, Kyoto, Japan). Single-cell suspension of splenocytes was treated with ammonium chloride to lyse the red blood cells; they were then washed, counted, and suspended in RPMI supplemented with 10% FBS, 50 μ M 2-mercaptoethanol, 1% antibiotic cocktail, non-essential amino acids solution, 1 mM sodium pyruvate, and 10 mM Hepes to a final concentration of 1×10^7 cells/ml.

Antigen-specific cytokine responses. Antigen-specific cytokine responses were evaluated using culturing splenocytes (5×10^6 cells/well) stimulated with OVA (1 mg/ml) *in vitro*. Cells were incubated at 37 $^{\circ}$ C for 72 h. Culture supernatants from *in vitro* unstimulated and OVA-stimulated cells were analyzed by the Bio-Plex Multiplex Cytokine Assay (Bio-Rad Laboratories, Hercules, CA) according to the manufacturer's instructions. The assay was read on a Luminex 100 (Austin, TX), and analyzed using the Bio-Plex Manager software. The mean concentration of cytokines in supernatants from OVA-stimulated cells over the unstimulated background was calculated.

Statistical analysis. All results are expressed as means \pm SEM. Differences were compared using Bonferroni's method after analysis of variance (ANOVA).

Results and discussion

Development of novel mucosal vaccine adjuvants with high efficacy and safety has been expected. Among various adjuvant candidates, cytokines might be promising safe adjuvants because they are human-derived and able to enhance the primary and memory immune responses sufficiently to protect from various infections. In this study, we examined the potential of TNF superfamily cytokines as mucosal vaccine adjuvants.

In this study, we used 16 different TNF superfamily cytokines (APRIL, BAFF, 4-1BBL, CD27L, CD30L, CD40L, EDA, GITRL, LIGHT, LT- α , OX40L, TL1A, TNF- α , TRAIL, TRANCE, and TWEAK). To examine TNF superfamily cytokines' potential as mucosal adjuvants, the mice were intranasally immunized with 100 μ g OVA plus each TNF superfamily cytokine (1 μ g/mice) three times at weekly intervals. Seven days after the last immunization, we examined the level of anti-OVA IgG responses in serum by ELISA (Fig. 1A). As a result, intranasal immunization with OVA plus TL1A exhibited significantly higher OVA-specific IgG responses in serum than those immunized with OVA alone. OVA-specific IgG level of TL1A immunized mice was of similar magnitude to that induced by CTB, one of the most effective mucosal adjuvants. In addition, intranasal immunization with OVA plus APRIL or TNF- α also showed strong OVA-specific IgG responses in serum.

Murine serum IgG subclass responses have been used to assess the type of immune responses elicited by immunization with IgG1 indicative of Th2-type responses and IgG2a indicative of Th1-type responses. To assess the type of immune response induced by TNF superfamily cytokines, IgG subclass studies were also examined (Fig. 1B and C). As a result, OVA-specific IgG1 was significantly high in mice immunized with OVA plus TL1A and TNF- α , which are as strong as CTB. Mice immunized with OVA plus APRIL also tend to show strong OVA-specific IgG1 responses. On the other hand, APRIL showed the highest OVA-specific IgG2a responses as well as CTB. These results indicated that APRIL, TL1A, and TNF- α could induce strong immune responses via nasal administration and also induce an antigen-specific Th2-type immune response.

Next, in order to identify the characteristics of TNF superfamily cytokines as mucosal adjuvants, we examined the OVA-specific IgA responses in nasal washes from immunized mice as well as vaginal washes and fecal extracts, which are not administration sites (Fig. 2). In nasal washes, OVA-specific IgA level of TL1A immunized mice were significantly higher than OVA alone immunized mice, and this magnitude was similar to that induced by CTB (Fig. 2A). Mice immunized with OVA plus APRIL or TNF- α also tended to show strong OVA-specific IgA responses. In vaginal washes and fecal extracts, TL1A and TNF- α showed the highest OVA-specific IgA responses among TNF superfamily cytokines, while these magnitudes were lower than those immunized with OVA plus CTB (Fig. 2B and C). These results indicate that nasal immunization




Fig. 1. Serum OVA-specific IgG responses by nasal immunization with OVA plus TNF superfamily cytokines. BALB/c mice were intranasally immunized with OVA alone, OVA plus CTB, or OVA plus each TNF superfamily cytokine three times at weekly intervals. Serum was collected 7 days after the last immunization and analyzed by ELISA for OVA-specific (A) total IgG, (B) IgG1, and (C) IgG2a responses at a 500-fold serum dilution. Data are presented as means \pm SEM ($n = 5$; * $P < 0.01$ versus value for OVA alone treated group by ANOVA).




Fig. 2. OVA-specific mucosal IgA responses by nasal immunization with OVA plus TNF superfamily cytokines. BALB/c mice were intranasally immunized with OVA alone, OVA plus CTB, or OVA plus each TNF superfamily cytokines once a week for 3 weeks. Mucosal secretions were collected 7 days following the last immunization and then OVA-specific IgA responses in (A) nasal wash, (B) vaginal wash and (C) fecal extract were determined by ELISA. Data are presented as means \pm SEM ($n = 5$; * $P < 0.05$, ** $P < 0.01$ versus value for OVA alone treated group by ANOVA).

with TL1A effectively induced both antigen-specific systemic and mucosal immune responses, and indicated that TL1A might be a new candidate for mucosal vaccine adjuvants replacing toxin-based adjuvants. Among these cytokines, CD40–CD40L interaction is also known to play an important role in the generation of antigen-specific IgA positive B cells, and mount specific IgA responses to orally or parenterally administered antigens [9,10]. Indeed, Nimomiya et al. showed that intranasal administration of anti-CD40 antibody with antigens from the influenza virus induced protective immunity against influenza virus [11]. Our results showed that intranasal administration of CD40L could not enhance mucosal immunity against antigens, but the precise reason of these controversial results was unknown.

To clarify the mechanisms of immune response by each TNF superfamily cytokine, the release profiles of cytokines from splenocytes of immunized mice were analyzed. Culture supernatants from OVA-stimulated splenocytes collected from immunized mice were assessed for Th2-type cytokines IL-4 (Fig. 3A) and IL-5 (Fig. 3B) and Th1-type cytokines interferon- γ (IFN γ) (Fig. 3C) and TNF- α (Fig. 3D), using a multiplexed immunobeads assay. Splenocytes from mice immunized with OVA plus APRIL, TNF- α , or TL1A exhibited higher levels of Th2-type cytokines (IL-4 and IL-5) than those responses induced by OVA alone (Fig. 3A and B). In contrast, there was little difference in Th1-type cytokine (IFN- γ and TNF- α)

secretion in all types of immunized mice (Fig. 3C and D). These results suggest that APRIL, TNF- α , and TL1A induced more strongly polarized Th2-type immune responses when used as mucosal vaccine adjuvants.

Our results indicate that TL1A induced the strongest mucosal immunity among the TNF superfamily cytokines. This is the first report to demonstrate TL1A mucosal adjuvant activity, induced antigen-specific systemic and mucosal immune responses in mice. The most recently identified member of the TNF superfamily, TL1A, is known to bind only to death receptor (DR) 3 expressed primarily on activated lymphocytes [12]. TL1A is also expressed on endothelial cells, normal lymphocytes, plasma cells, monocytes, and dendritic cells (DCs) [13,14]. TL1A can induce IFN- γ production of IL-12 and IL-18 primed T cells, whereas TL1A does not enhance IL-4 production from Th2 cells by systemic injection [15,16]. Therefore, it was believed that the TL1A/DR3 pathway played a dominant role in the Th1-type immune response by mucosal T cells in the inflamed mucosal site. On the other hand, a recent study showed that TL1A may act as soluble mediator or as cell-bound ligand to trigger DR3 on NKT and T cells, and this pair appears to provide an ear' signal for Th2-type cytokine production such as IL-4 and IL-13 [17]. We showed that the OVA-specific immune response of TL1A immunized mice was characterized by high levels of serum IgG1 and increased production of IL-4 and IL-5 from splenocytes of




Fig. 3. Cytokine responses induced by nasal immunization with OVA plus adjuvants. BALB/c mice were intranasally immunized with OVA alone, OVA plus CTB, OVA plus each TNF superfamily cytokine three times at weekly intervals. Seven days after the last immunization, splenocytes from each group were cultured with 1 mg/ml OVA. Culture supernatants were harvested after 3 days of incubation, and then OVA-specific (A) IL-4, (B) IL-5, (C) IFN γ , and (D) TNF- α productions in culture supernatant were analyzed using the Bio-Plex Multiplex Cytokine Assay. Data are presented as means \pm SEM ($n = 4$; * $P < 0.05$, ** $P < 0.01$ versus value for PBS treated group by ANOVA; * $P < 0.01$ versus value for OVA alone treated group by ANOVA).

immunized mice, suggesting a Th2-type immune response. The administration route of antigen immunization might be critical for influencing the type of immune response, although the precise reason for these contradictory results remains unclear. We are currently examining the mechanism of TL1A-induced Th2-type immune responses in more detail. In addition, the potential of TL1A as a mucosal vaccine adjuvant should be enhanced because the strength of immune responses by TL1A was lower than that of CTB. We have developed a novel technology to produce mutant cytokines using phage display [18–21]. We previously produced a bioactive mutant TNF- α with 6-fold stronger *in vitro* bioactivity and 13-fold stronger *in vivo* bioactivity compared with wild-type TNF- α [20]. We are now attempting to generate mutant TL1A with improved adjuvanticity.

We showed that APRIL and TNF- α also had the potential to function as a mucosal vaccine adjuvant, although the strength of immune responses in those immunized mice was lower than mice immunized with TL1A. The analysis of knockout mice suggested that APRIL would deliver B cell activation signals and induce IgA production against antigens from pathogenic microorganisms and viruses [22]. In addition, it was also reported that TNF- α played an important role in IgA production [23]. Future examination is needed to determine a more precise mechanism of IgA production by APRIL and TNF- α .

Regulation of Th1- and Th2-type immune responses is the major goal for the development of mucosal vaccines because these types of immune responses would control protective immunity against viral and bacterial infections by maximizing antigen-specific antibodies and CTL responses [1,3]. To induce both antigen-specific antibodies and CTL responses, combinatorial administration of TL1A with another mucosal adjuvant, which can induce Th1-type immune responses, is applicable. We have already screened the other cytokines and succeeded in finding candidates that can effectively induce CTL responses at the mucosal site. The combinatorial effect of the cytokines and TL1A as a mucosal vaccine adjuvant is now under examination.

In summary, our study showed that TL1A induced two layers of protective immunity when administered intranasally with a vaccine antigen. Our results indicate that TL1A is an effective mucosal adjuvant.

Acknowledgments

The authors declare no conflict of interests. This study was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) and Japan Society for the Promotion of Science (JSPS), by grants from the Ministry of Health, Labor, and Welfare in Japan and from the Japan Health Sciences Foundation and by the grant from Takeda Science Foundation.

References

- [1] K. Eriksson, J. Holmgren, Recent advances in mucosal vaccines and adjuvants, *Curr. Opin. Immunol.* 14 (2002) 666–672.
- [2] B.F. Haynes, R.J. Shattock, Critical issues in mucosal immunity for HIV-1 vaccine development, *J. Allergy Clin. Immunol.* 122 (2008) 3–9. quiz 10–11.
- [3] J. Holmgren, C. Czerkinsky, Mucosal immunity and vaccines, *Nat. Med.* 11 (2005) S45–S53.
- [4] S.L. Gorbach, C.M. Khurana, Toxigenic *Escherichia coli* in infantile diarrhea in Chicago, *J. Lab. Clin. Med.* 78 (1971) 981–982.
- [5] M. Mutsch, W. Zhou, P. Rhodes, M. Bopp, R.T. Chen, T. Linder, C. Spyr, R. Steffen, Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland, *N. Engl. J. Med.* 350 (2004) 896–903.
- [6] Y. Collette, A. Gilles, P. Pontarotti, D. Olive, A co-evolution perspective of the TNFSF and TNFRSF families in the immune system, *Trends Immunol.* 24 (2003) 387–394.
- [7] T. Hehlhans, K. Pfeffer, The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games, *Immunology* 115 (2005) 1–20.
- [8] K. Tamada, L. Chen, Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules, *Cancer Immunol. Immunother.* 55 (2006) 355–362.
- [9] T. Kawabe, T. Naka, K. Yoshida, T. Tanaka, H. Fujiwara, S. Suematsu, N. Yoshida, T. Kishimoto, H. Kikutani, The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation, *Immunity* 1 (1994) 167–178.
- [10] P. Bergqvist, E. Gardby, A. Stensson, M. Bemark, N.Y. Lycke, Gut IgA class switch recombination in the absence of CD40 does not occur in the lamina propria and is independent of germinal centers, *J. Immunol.* 177 (2006) 7772–7783.
- [11] A. Ninomiya, K. Ogasawara, K. Kajino, A. Takada, H. Kida, Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice, *Vaccine* 20 (2002) 3123–3129.
- [12] T.S. Migone, J. Zhang, X. Luo, L. Zhuang, C. Chen, B. Hu, J.S. Hong, J.W. Perry, S.F. Chen, J.X. Zhou, Y.H. Cho, S. Ullrich, P. Kanakaraj, J. Carrell, E. Boyd, H.S. Olsen, G. Hu, L. Pukac, D. Liu, J. Ni, S. Kim, R. Gentz, P. Peng, P.A. Moore, S.M. Ruben, P. Wei, TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator, *Immunity* 16 (2002) 479–492.
- [13] G. Bamiyas, M. Mishina, M. Nyce, W.G. Ross, G. Kollias, J. Rivera-Nieves, T.T. Pizarro, F. Cominelli, Role of TL1A and its receptor DR3 in two models of chronic murine ileitis, *Proc. Natl. Acad. Sci. USA* 103 (2006) 8441–8446.
- [14] J.L. Prehn, L.S. Thomas, C.J. Landers, X. Luo, S.C. Cha, P. Wei, S.R. Targan, The T cell costimulator TL1A is induced by Fc γ signaling in human monocytes and dendritic cells, *J. Immunol.* 178 (2007) 4033–4038.
- [15] J.L. Prehn, S. Mehdizadeh, C.J. Landers, X. Luo, S.C. Cha, P. Wei, S.R. Targan, Potential role for TL1A, the new TNF-family member and potent costimulator of IFN- γ , in mucosal inflammation, *Clin. Immunol.* 112 (2004) 66–77.
- [16] K.A. Papadakis, D. Zhu, J.L. Prehn, C. Landers, A. Avanesyan, G. Lafkas, S.R. Targan, Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN- γ production by peripheral blood and mucosal CCR9+ T lymphocytes, *J. Immunol.* 174 (2005) 4985–4990.
- [17] L. Fang, B. Adkins, V. Deyev, E.R. Podack, Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation, *J. Exp. Med.* 205 (2008) 1037–1048.
- [18] Y. Yamamoto, Y. Tsutsumi, Y. Yoshioka, T. Nishibata, K. Kobayashi, T. Okamoto, Y. Mukai, T. Shimizu, S. Nakagawa, S. Nagata, T. Mayumi, Site-specific PEGylation of a lysine-deficient TNF- α with full bioactivity, *Nat. Biotechnol.* 21 (2003) 546–552.
- [19] Y. Yoshioka, Y. Tsutsumi, S. Ikemizu, Y. Yamamoto, H. Shibata, T. Nishibata, Y. Mukai, T. Okamoto, M. Taniyai, M. Kawamura, Y. Abe, S. Nakagawa, S. Nagata, Y. Yamagata, T. Mayumi, Optimal site-specific PEGylation of mutant TNF- α improves its antitumor potency, *Biochem. Biophys. Res. Commun.* 315 (2004) 808–814.
- [20] H. Shibata, Y. Yoshioka, S. Ikemizu, K. Kobayashi, Y. Yamamoto, Y. Mukai, T. Okamoto, M. Taniyai, M. Kawamura, Y. Abe, S. Nakagawa, T. Hayakawa, S. Nagata, Y. Yamagata, T. Mayumi, H. Kamada, Y. Tsutsumi, Functionalization of tumor necrosis factor- α using phage display technique and PEGylation improves its antitumor therapeutic window, *Clin. Cancer Res.* 10 (2004) 8293–8300.
- [21] H. Shibata, Y. Yoshioka, A. Ohkawa, K. Minowa, Y. Mukai, Y. Abe, M. Taniyai, T. Nomura, H. Kayamuro, H. Nabeshi, T. Sugita, S. Imai, K. Nagano, T. Yoshikawa, T. Fujita, S. Nakagawa, A. Yamamoto, T. Ohta, T. Hayakawa, T. Mayumi, P. Vandennebeele, B.B. Aggarwal, T. Nakamura, Y. Yamagata, S. Tsunoda, H. Kamada, Y. Tsutsumi, Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor- α antagonist, *J. Biol. Chem.* 283 (2008) 998–1007.
- [22] E. Castigli, S. Scott, F. Dedeoglu, P. Bryce, H. Jabara, A.K. Bhan, E. Mizoguchi, R.S. Geha, Impaired IgA class switching in APRIL-deficient mice, *Proc. Natl. Acad. Sci. USA* 101 (2004) 3903–3908.
- [23] H. Tezuka, Y. Abe, M. Iwata, H. Takeuchi, H. Ishikawa, M. Matsushita, T. Shiohara, S. Akira, T. Ohteki, Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells, *Nature* 448 (2007) 929–933.

